中美洲胃癌治疗市场 – 行业趋势和 2029 年预测

中美洲胃癌治疗市场分析与见解

胃腺癌是全球第四大常见癌症类型，也是全球第二大癌症死亡原因。胃癌是一种始于胃的细胞异常生长。胃癌，也称为胃癌，可影响胃的任何部位。在世界上大多数地区，胃癌形成于胃的主要部分（胃体）。但在美国，胃癌更可能影响食管与胃交界的区域。这个区域称为胃食管连接处。

随着老年人口的增长，胃肠道肿瘤的发病率也随之上升，导致胃癌治疗数量不断增加。因此，据估计，老年人口的增长是市场增长的主要驱动因素。

胃癌治疗是支持性的，旨在减缓疾病的进展。Data Bridge Market Research 分析称，在 2022 年至 2029 年的预测期内，遗传性胃癌治疗将以 7.2% 的复合年增长率增长。

Gastric Cancer Treatment Market Dynamics

Drivers

• Increase in Incidence of Gastrointestinal Tumours, Lymphoma, and Adenocarcinoma

The increased incidence of gastrointestinal tumors, lymphoma, and adenocarcinoma is increasing the demand for the early detection and diagnosis via utilizing the latest technology, thereby propelling the growth of the Central America gastric cancer treatment market.

• Rise in Alcohol Consumption and Surge in Smoking

The combined use of cigarettes and alcohol poses health concerns and severe public health issue that collectively lead to gastric cancer. A chemical chain reaction occurs every time a smoker inhales a lit cigarette, producing dozens of hazardous chemicals. Cigarette smoke contains substances inhaled through the lips, through the tongue and mouth, down the throat, and into the lungs, producing inflammation and exposing that aero-digestive tract to cancer-causing chemicals.

Also, the high incidence of obesity in these countries is expected to drive the growth of Central America gastric cancer treatment market.

Furthermore, Increase in strategic initiatives by key players, advancement in medical technology, recent advancements in gastric cancer treatment, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the gastric cancer treatment market.

Opportunities

• Healthcare Expenditure of Central American Countries

Moreover, the increase in awareness and treatment-seeking rate and emerging reimbursement policies for the treatment will boost new opportunities for the market's growth rate.

Also, the increasing drug approvals will provide beneficial opportunities for the gastric cancer treatment market in the forecast period of 2022-2029. Also, the partnership and agreement by major players will escalate the growth rate of the gastric cancer treatment market in the future.

Restraints/Challenges

However, the costs associated with other medical care and interventions (such as surgical interventions and radiotherapy) and supportive care (such as anti-emetics and hematopoietic growth factors) would make overall care even more unaffordable. Even with insurance coverage, patients living with cancer in many countries have reported financial stress, to the extent that they may lower the treatment dose, partially fill prescriptions, or even forego treatment altogether.

This gastric cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Gastric Cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Gastric cancer disease is the 5th most commonly diagnosed cancer in the world, and the 7th most prevalent. Gastric cancer is more prevalent in males. In developed countries, gastric cancer is 2.2 times more likely to be diagnosed in males than females. In developing countries, this ratio is 1.83. In 5 countries worldwide, gastric cancer has the highest incidence among all cancers for males.

Most cancers of the stomach (about 90% to 95%) are adenocarcinomas. These cancers develop from the gland cells in the innermost lining of the stomach (the mucosa). Stomach cancer mostly affects older people. The average age of people when they are diagnosed is 68. About 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. The lifetime risk of developing stomach cancer is higher in men (about 1 in 96) than in women (about 1 in 152). But each person's risk can be affected by many other factors

The gastric cancer treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Post COVID-19 Impact on Gastric Cancer Treatment Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.

Recent Development

• 2021 年 3 月，安进与专注于开发免疫肿瘤学和靶向癌症疗法的临床阶段生物技术公司 Five Prime Therapeutics 宣布了一项协议，安进将收购 Five Prime Therapeutics。此次收购还将包括用于治疗胃癌的 3 期临床试验 Bemarituzumab

中美洲胃癌治疗 市场范围

中美洲胃癌治疗市场分为六个显著的细分市场，根据类型、阶段、治疗、给药途径、最终用户和分销渠道进行划分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，以便做出战略决策，确定核心市场应用。

类型

• 腺癌
• 淋巴瘤
• 胃肠道间质瘤
• 类癌肿瘤
• 其他的

根据类型，市场分为腺癌、淋巴瘤、胃肠道间质瘤、类癌瘤等。

阶段

• 第一阶段
• 第二阶段
• 第三阶段
• 第四阶段
• 其他的

根据阶段，市场分为第一阶段、第二阶段、第三阶段、第四阶段和其他阶段。

治疗

• 化疗
• 靶向治疗
• 免疫检查点抑制剂
• 其他的

根据治疗方法，市场分为化疗、靶向治疗、免疫治疗和其他治疗。

给药途径

• 口服

• 肠外

根据给药途径，市场分为口服和肠外给药。

最终用户

• 医院
• 专科诊所
• 研究与学术机构
• 其他的

根据最终用户，中美洲胃癌治疗市场分为医院、专科诊所、研究和学术机构等。

分销渠道

• 零售药店
• 医院药房
• 其他的

中美洲胃癌治疗市场也根据分销渠道细分为零售药房、医院药房和其他。

管道分析

药物管线分析包括Zolbetuximab (IMAB362)加mFOLFOX6、Nivolumab加Ipilimumab、Pembrolizumab (MK-3745)加顺铂、Regorafenib (Stivarga, BAY73-4506)、lapatinib、NCT03653507、Durvalumab或Placebo、FLOT化疗等多种管线疗法。安斯泰来制药、百时美施贵宝、默沙东、拜耳、诺华等公司均参与了改善胃癌治疗的潜在药物研发。

胃癌治疗市场区域分析/见解

对胃癌治疗市场进行了分析，并按国家、类型、阶段、治疗、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势。

胃癌治疗市场报告涉及的国家包括哥斯达黎加、危地马拉、巴拿马、多米尼加共和国和中美洲其他国家。

哥斯达黎加在市场份额和市场收入方面占据胃癌治疗市场的主导地位，并将在预测期内继续保持主导地位。这是因为该国拥有主要的关键参与者和发达的医疗保健基础设施。

报告的国家部分还提供了影响单个市场因素和市场法规变化的信息，这些因素和变化会影响市场的当前和未来趋势。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测单个国家市场情况的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因本土和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。

竞争格局和中美洲胃癌治疗市场 份额分析

胃癌治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对胃癌治疗的关注有关。

中美洲胃癌治疗市场的一些主要公司包括 F. Hoffmann-La Roche Ltd.、默克公司、辉瑞公司、梯瓦制药工业有限公司、阿斯利康、拜耳公司、诺华公司、百时美施贵宝公司、礼来公司、Laboratorio Varifarma SA、Seven pharma、杨森全球服务有限公司（强生服务公司的子公司）和赛诺菲等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、全球与区域和供应商份额分析。如有进一步询问，请要求分析师致电。

SKU-68005